Efficacy and Safety of Selumetinib in Pediatric Patients With Neurofibromatosis Type 1: A Systematic Review and Meta-analysis.

Jisun Hwang Hee Mang Yoon Beom-Hee LeePyeong Hwa KimKyung Won Kim

Published in: Neurology (2022)

Our results indicate that selumetinib is an effective and safe treatment for pediatric patients with symptomatic, inoperable plexiform neurofibromas. Further larger-scale randomized controlled studies are needed to confirm the long-term outcome of patients treated with this drug.

Keyphrases

double blind
open label
phase iii
placebo controlled
emergency department
randomized controlled trial
squamous cell carcinoma
radiation therapy
case control
drug induced